Company Profile

Antares Pharma Inc (AKA: Medi-Ject Corporation)
Profile last edited on: 11/16/2023      CAGE: 0ZUN9      UEI: HUPMBS878KL3

Business Identifier: Needle-free drug delivery injection system
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

100 Princeton Street Suite 300
Ewing, NJ 08628
   (609) 359-3020
Location: Multiple
Congr. District: 12
County: Mercer

Public Profile

As of late May 2022, it was announced that Halozyme (NASDAQ: HALO) had completed its acquisition of Antares Pharma, Inc., creating a leading drug delivery business with broadly licensable opportunities across the ENHANZE┬« and Antares┬ĺ auto injector technologies. Antares Pharma Inc - formerly known as Medi-Ject Corporation - functioned as a drug delivery company focused on developing, manufacturing and marketing needle-free injection systems for the self-administration of a wide range of parenteral drugs. The firm's technology is grounded in Needle-free drug delivery injection system use of a narrow, high-pressure stream of liquid. With only a minimal SBIR involvement - and that some years ago - the firm's Medi-Jector Vision system is a handheld device that injects a thin, high-pressure stream of liquid, eliminating the need for a needle. The Vision system is used primarily for the delivery of insulin and of human growth hormones for children; it is available over-the-counter and by prescription in the US and is also sold overseas. Antares was formed when Medi-Ject completed a reverse acquisition of Permatec,

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
1993 1 NIH $50,000
Project Title: Improved jet injection devices for rehabilitation

Key People / Management

  Paul K Wotton -- President

  Lawrence Christian -- Chief Financial Officer

  Kenneth W Dunlap

  Roger G Harrison -- Former President

  Venus Melendez -- Chief Business Officer

  Jack E Stover